ANIX Archives - Page 2 of 2

Developments

Anixa Biosciences receives U.S. notice of additional ovarian cancer vaccine patent

The U.S. Patent and Trademark Office (USPTO) issued a notice of allowance broadening protection of Anixa Biosciences’ (NASDAQ:ANIX) novel ovarian cancer vaccine technology, which has been exclusively licensed from, and...

July 27, 2023

Feature

Anixa vaccines targeting unique mechanism in breast, ovarian cancer

Anixa Biosciences (NASDAQ:ANIX) is targeting a unique technology in two early-stage, first-in-class prophylactic cancer vaccines with the potential to prevent cancer cells from forming into breast and ovarian tumors.

July 25, 2023

Developments

Anixa Biosciences breast cancer vaccine featured in Daily Mail article

A Phase 1 trial of Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine and women survivors were featured in an article on the website of England’s Daily Mail newspaper. Anixa’s CEO, Amit Kumar, Ph.D., described the...

July 17, 2023

Developments

Anixa Biosciences receives Canadian patent for CAR-T cancer therapy technology

The Canadian Intellectual Property Office issued a patent covering Anixa Biosciences’ (NASDAQ:ANIX) novel chimeric antigen receptor T-cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar...

July 11, 2023

Developments

Anixa Biosciences in COVID-19 development pact with OntoChem

Anixa Biosciences (NASDAQ:ANIX) entered a strategic collaboration with OntoChem GmbH to discover and develop anti-viral drug candidates for COVID-19. “We believe that newly designed drugs that are purposefully developed...

April 20, 2020

Feature

Anixa Biosciences harnessing interactions between tumors and the immune system

Anixa Biosciences (NASDAQ:ANIX) is taking multiple approaches to fighting cancer, developing both a diagnostic and therapeutics, such as a cancer immunotherapy and vaccine, to overcome immuno-suppression. Anixa...

March 3, 2020

Executive Moves

Anixa Biosciences names cancer vaccine pioneer, Dr. Ian Frazer to SAB

Ian Frazer Anixa Biosciences (NASDAQ:ANIX) appointed cancer vaccine pioneer, Dr. Ian Frazer, to its scientific advisory board. Dr. Frazer is a leading immunologist recognized as one of the first scientists to...

October 10, 2019

Tag - ANIX

Anixa Biosciences receives U.S. notice of additional ovarian cancer vaccine patent

Anixa vaccines targeting unique mechanism in breast, ovarian cancer

Anixa Biosciences breast cancer vaccine featured in Daily Mail article

Anixa Biosciences receives Canadian patent for CAR-T cancer therapy technology

Anixa Biosciences in COVID-19 development pact with OntoChem

Anixa Biosciences harnessing interactions between tumors and the immune system

Anixa Biosciences names cancer vaccine pioneer, Dr. Ian Frazer to SAB

General

More